Conjugate Or Complex Of Monoclonal Or Polyclonal Antibody, Immunoglobulin, Or Fragment Thereof With Nonimmunoglobulin Material Patents (Class 424/178.1)
  • Patent number: 10656167
    Abstract: The present invention provides methods of dosing Factor VIII or Factor IX chimeric and hybrid polypeptides. The present invention further provides high-sensitivity methods of quantifying an amount of activated FIX protein in a test sample.
    Type: Grant
    Filed: July 25, 2012
    Date of Patent: May 19, 2020
    Assignee: BIOVERATIV THERAPEUTICS INC.
    Inventors: Jurg Sommer, Haiyan Jiang, Xin Zhang, Buyue Yang, Glenn Pierce
  • Patent number: 10654904
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: October 2, 2019
    Date of Patent: May 19, 2020
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Andrea Mahr, Toni Weinschenk, Valentina Goldfinger, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Patent number: 10626187
    Abstract: Isolated antigen binding molecules that specifically bind to an anti-CD19 scFv comprising SEQ ID NO: 1 are provided. The antigen binding molecules can be used in the methods provided herein.
    Type: Grant
    Filed: September 27, 2017
    Date of Patent: April 21, 2020
    Assignee: Kite Pharma, Inc.
    Inventors: Jed Wiltzius, Stuart Sievers
  • Patent number: 10613081
    Abstract: A kit and method for evaluation of the quality and the operating parameters of any types of fully automated open ELISA instruments are disclosed. The kit and method can be used to reliably assess quality control parameters including precision, volume removal accuracy, plate reader accuracy, plate reader linearity, plate washer quality, drift absence, and carryover absence. The evaluation can be completed in a timely and cost-effective manner and provide laboratories with the ability to readily validate the operation and performance of a fully automated ELISA instrument.
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: April 7, 2020
    Inventors: Alireza Palangi, Samira Bayat Bidkorpeh
  • Patent number: 10610587
    Abstract: This invention relates to an adjuvant composition containing at least one binding molecule for neutralizing influenza virus and a vaccine composition containing the same. The composition containing at least one binding molecule for neutralizing influenza virus is capable of increasing the effects of a vaccine, and can thus be used as an adjuvant, which increases an immune response upon vaccine administration, and is very useful in the prevention of diseases caused by viruses.
    Type: Grant
    Filed: September 13, 2018
    Date of Patent: April 7, 2020
    Assignee: CELLTRION INC.
    Inventors: Shin Jae Chang, Soo Young Lee, Byung Pil Lim, Pan Kyeom Kim, Sang Tae Park, Jung Sun Ahn, Eun Bee Park, Sun Ju Keum, Man Ki Song, Jung Ah Choi
  • Patent number: 10604580
    Abstract: The present invention relates to combination therapies with anti-CD38 antibodies and all-trans retinoic acid.
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: March 31, 2020
    Assignee: JANSSEN BIOTECH, INC.
    Inventors: Henk M. Lokhorst, Tuna Mutis, Inger S Nijhof, Niels Van de Donk
  • Patent number: 10603338
    Abstract: A method is provided for the poly signal activation of apoptosis of malignant solid tumour cells, carried out by means of the targeted delivery of thallium salts by surface-modified MS2 phage virions, which contain a cyclic iRGD ligand that has a high affinity for the integrins avb3 and avb5 and is covalently bound with the shell and with the core, which contains genomic RNA and thallium salts. Complex, efficient, prolonged cytotoxic action is provided on focal and metastatic clusters of malignant solid tumour cells, while minimizing undesirable side effects on the healthy cells of an organism.
    Type: Grant
    Filed: October 21, 2016
    Date of Patent: March 31, 2020
    Assignee: OBSHESTVO S ORGANICHENNOI OTVETSTVENNOST'YU “BIOTEHNOLOGIYA”
    Inventors: Tat'yana Nikolaevna Bol'shakova, Ekaterina Feodorovna Kolesanova, Ekaterina Ur'evna Rybalkina, Igor′ Gennad'evich Sivov
  • Patent number: 10603389
    Abstract: The present disclosure provides antibody drug conjugates that bind human cMET, their methods of making, and their uses to treat patients having cancer.
    Type: Grant
    Filed: May 28, 2019
    Date of Patent: March 31, 2020
    Assignees: AbbVie Inc., AbbVie Biotherapeutics Inc.
    Inventors: Christian B. Allan, Louie Naumovski, Edward B. Reilly
  • Patent number: 10597433
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: July 5, 2019
    Date of Patent: March 24, 2020
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Andrea Mahr, Toni Weinschenk, Valentina Goldfinger, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Patent number: 10588972
    Abstract: The present invention relates to compositions and methods for destroying target cells in a patient using photodynamic therapy. In particular, the present invention provides a photosensitizing agent based on a small molecular weight (<50 kDa) protein or peptide or a small molecule that is conjugated to a phthalocyanine dye, such as IRDye® 700DX.
    Type: Grant
    Filed: June 2, 2015
    Date of Patent: March 17, 2020
    Assignee: LI-COR, INC.
    Inventor: Joy L. Kovar
  • Patent number: 10577429
    Abstract: The invention provides antibodies against Fibroblast Activation Protein (FAP) and methods of using the same.
    Type: Grant
    Filed: March 18, 2015
    Date of Patent: March 3, 2020
    Assignee: ROCHE GLYCART AG
    Inventors: Marina Bacac, Anne Freimoser-Grundschober, Ralf Hosse, Christian Klein, Ekkehard Moessner, Valeria G. Nicolini, Pablo Umana
  • Patent number: 10537644
    Abstract: The present invention provides novel and advantageous compositions having a linker capable of covalently coupling one or more free thiols of an antibody. Specifically, provided herein are the molecular structures, synthetic pathways, coupling mechanisms, and applications thereof as used in an antibody-drug conjugate (ADC).
    Type: Grant
    Filed: August 15, 2016
    Date of Patent: January 21, 2020
    Assignee: RC BIOTECHNOLOGIES, INC.
    Inventors: Chang Jiang Huang, Jianmin Fang, Hui Ye, Lezhi Zhang
  • Patent number: 10533059
    Abstract: The current invention discloses targeted drug delivery conjugates comprising a targeting moiety linked to a drug via a molecule having an affinity for the targeting moiety. Typically, the conjugate comprises a targeting ligand and a molecule of interest, e.g., a therapeutic agent. The targeting ligand and the molecule of interest are linked to each other via an affinity ligand. The affinity ligand is further covalently or non-covalently linked to a drug or therapeutic agent. The drug can be modified to make it more soluble and so that it cleaves from the linking molecule at the target site.
    Type: Grant
    Filed: March 11, 2015
    Date of Patent: January 14, 2020
    Assignee: AKAMARA THERAPEUTICS, INC.
    Inventors: Shiladitya Sengupta, Monideepa Roy, Nimish Gupta, Seikh Samad Hossain
  • Patent number: 10519218
    Abstract: A selective IL-6-trans-signalling inhibitor can be used to treat a variety of IL-6-mediated conditions, including inflammatory diseases and cancer. The inhibitor can safely be administered to humans at a variety of doses.
    Type: Grant
    Filed: December 1, 2015
    Date of Patent: December 31, 2019
    Assignee: FERRING B.V.
    Inventors: Ian Cottingham, Daniel Plaksin, Jérémy Duboeuf
  • Patent number: 10517969
    Abstract: A method for identifying a patient for cancer therapy can include administering a diagnostic dose of a detectably labeled first binding agent to a patient, the detectably labeled binding agent being capable of binding a molecular target. The method also includes selecting a patient for administration of a therapeutic dose of a second binding agent capable of binding a cellular target, wherein the selected patient exhibits a positive reading for the detectably labeled first binding agent. Furthermore, the method can include administering a therapeutic dose of the second binding agent to the patient.
    Type: Grant
    Filed: February 17, 2010
    Date of Patent: December 31, 2019
    Assignee: CORNELL UNIVERSITY
    Inventors: Neil H. Bander, Joseph Osborne, Stanley J. Goldsmith, Shankar Vallabhajosula
  • Patent number: 10513541
    Abstract: Disclosed are a mutated HPV11 L1 protein (or a variant thereof), a sequence encoding the same, a method for preparing the same, and a virus-like particle comprising the same, wherein the protein (or a variant thereof) and the virus-like particle can induce the generation of neutralizing antibodies against at least two HPV types (e.g. HPV11 and HPV6), and therefore can be used to prevent infection by said at least two HPV types, and a disease caused by said infection, such as cervical cancer and condyloma acuminatum. Also disclosed is use of the protein and the virus-like particle in the manufacture of a pharmaceutical composition or a vaccine for preventing infection by said at least two HPV types, and a disease caused by said infection, such as cervical cancer and condyloma acuminatum.
    Type: Grant
    Filed: December 2, 2016
    Date of Patent: December 24, 2019
    Assignees: Xiamen University, Xiamen Innovax Biotech Co., Ltd.
    Inventors: Shaowei Li, Daning Wang, Xinlin Liu, Zhihai Li, Jun Zhang, Ningshao Xia
  • Patent number: 10513545
    Abstract: The present invention relates to: a fusion polypeptide in which an anti-inflammatory polypeptide and a ferritin monomer fragment are bound; and a pharmaceutical composition for treating inflammatory diseases, containing the same as an active ingredient and, more specifically, to: a fusion polypeptide in which an anti-inflammatory polypeptide is fused to an N-terminus and/or a C-terminus of a ferritin monomer fragment from which a portion of a fourth loop and a fifth helix, of a human derived ferritin monomer, are removed; and a use thereof for treating inflammatory diseases.
    Type: Grant
    Filed: September 2, 2016
    Date of Patent: December 24, 2019
    Assignees: KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION, KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Jong-Sup Bae, In-San Kim, Won Hwa Lee, Jun Young Seo, So Youn Kim
  • Patent number: 10508131
    Abstract: Disclosed is a method for refolding a protein or peptide that does not contain essential disulfides and that contains at least one free cysteine residue. Also disclosed are polymer IFN-? conjugates that have been created by the chemical coupling of polymers such as polyethylene glycol moieties to IFN-?, particularly via a free cysteine in the protein. Also disclosed are analogs of bioactive peptides that may be used to create longer acting versions of the peptides, including analogs of glucagon, glucagon-like peptide-1 (GLP-1), GLP-2, Gastric inhibitory peptide (GIP), PYY, exendin, ghrelin, gastrin, amylin, and oxyntomodulin.
    Type: Grant
    Filed: November 17, 2017
    Date of Patent: December 17, 2019
    Assignee: Bolder Biotechnology, Inc.
    Inventors: George N. Cox, Mary S. Rosendahl
  • Patent number: 10502746
    Abstract: One aspect as reported herein is a method for detecting a rat antibody in a serum or plasma sample (obtained) from a mouse comprising the steps of a) providing the sample to be analyzed, b) incubating said serum or plasma sample with an antibody that specifically binds to rat IgG and that does not specifically bind to mouse IgG, wherein the antibody is i) a mixture of an antibody binding to rat kappa light chain and an antibody binding to rat lambda light chain, or ii) a mixture of an antibody binding to rat IgG1 with an avidity of 4.1×1010 M?1 or more, an antibody binding to rat IgG2a with an avidity of 8.6×109 M?1 or more, an antibody binding to rat IgG2b with an avidity of 6.4×1010 M?1 or more and an antibody binding to rat IgG2c with an avidity of 9.
    Type: Grant
    Filed: September 18, 2015
    Date of Patent: December 10, 2019
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Kay-Gunnar Stubenrauch, Uwe Wessels
  • Patent number: 10485881
    Abstract: Described herein are nanoparticle drug conjugates (NDCs), which, in certain embodiments, comprise a non-toxic, multi-modality, clinically proven silica-based nanoparticle platform with covalently attached drug molecules/moieties. The nanoparticle drug conjugates (NDCs) demonstrate imaging capability and targeting ligands which efficiently clear through the kidneys. Furthermore, the conjugates incorporate therapeutic agents for cancer detection, prevention, and/or treatment.
    Type: Grant
    Filed: September 21, 2018
    Date of Patent: November 26, 2019
    Assignees: Memorial Sloan Kettering Cancer Center, Cornell University
    Inventors: Michelle S. Bradbury, Barney Yoo, Ulrich Wiesner, Kai Ma
  • Patent number: 10485868
    Abstract: The present invention develops a vaccine composition against and treatment or prevention on inflammation and lung injury (particularly hyperoxia-induced lung injury) and progression of periodontitis. Tn immunization increases serum anti-Tn antibody titers, while it decreases lavaged protein and cytokines, and also decreases mean linear intercept and lung injury score. Furthermore, the improvement in lung injury is accompanied by a decrease in NF-?B activity.
    Type: Grant
    Filed: September 19, 2017
    Date of Patent: November 26, 2019
    Assignee: TAIPEI MEDICAL UNIVERSITY
    Inventors: Jaulang Hwang, Chung-Ming Chen
  • Patent number: 10463750
    Abstract: This disclosure describes compositions and methods for selectively recruiting antigen-specific T cells and re-direct them to kill targeted cells, particularly tumor cells. This approach permits selective engagement of specific effector cell populations and, by using nanoparticles, overcomes the geometric limitations associated with previous approaches.
    Type: Grant
    Filed: February 14, 2014
    Date of Patent: November 5, 2019
    Assignee: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Jonathan Schneck, Christian Schuetz
  • Patent number: 10457719
    Abstract: In certain embodiments, this present invention provides antibodies and Fc fusion proteins with enhanced pharmacokinetics, such as biotinylated antibodies or biotinylated Fc fusion polypeptides.
    Type: Grant
    Filed: September 17, 2008
    Date of Patent: October 29, 2019
    Assignee: The Jackson Laboratory
    Inventors: Derry Roopenian, Gregory Christianson
  • Patent number: 10428131
    Abstract: The disclosure provides GITRL fusion polypeptide subunits comprising an IgG Fc domain, a trimerization domain, and the receptor binding domain of GITR ligand, where the fusion polypeptide subunits can self-assemble into hexameric proteins. Also provided are methods of making fusion polypeptide subunits and hexameric proteins, and methods of use, e.g., treatment of cancer.
    Type: Grant
    Filed: August 11, 2016
    Date of Patent: October 1, 2019
    Assignee: MEDIMMUNE LIMITED
    Inventors: Ross Anthony Stewart, Natalie Jo Tigue, Lesley Lynn Young, Daniel Ramsay Higazi, Lisa Bamber, Sudharsan Sridharan, Rebecca Leyland, Nicholas Mason Durham
  • Patent number: 10383932
    Abstract: A combination of components to promote an innate and adaptive immune response comprising of a TAA/ecdCD40L vaccine and a complex between the CD1d receptor and an alpha galactosyl ceramide like glycolipid (AGCLGL), to activate NKT cells and activate the CD40 receptor on the DCs and increase the level of the adaptive immune response induced by the TAA/ecdCD40L vaccine to the TAA. The result and advantage of using both the TAA/ecdCD40L vaccine and the ?-galactosylceramide-CD1d complex (or a related bacterial or other antigen related to ?-galactosylceramide) to stimulate the immune response through the CD40L/CD40 axis on dendritic cells, is that the magnitude of the stimulation is robust and increased significantly more than additive—i.e. synergistically due to the interaction, cross-talk and/or cross-stimulation of the glycolipid-CD1d pathway and TAA/ecdCD40L pathway. As a result, a potent immune response is induced against lipid target antigens as well as protein target antigens.
    Type: Grant
    Filed: April 26, 2016
    Date of Patent: August 20, 2019
    Assignee: MicroVAX, LLC
    Inventor: Albert B. Deisseroth
  • Patent number: 10370413
    Abstract: Compounds which selectively bind to and inhibit the activity of the potassium channel Kv1.3 are described. Pharmaceutical compositions comprising such compounds and the use of said compounds and said pharmaceutical compositions for the treatment or prevention of autoimmune diseases, obesity, parodontitis and/or tissue transplant rejection are also described.
    Type: Grant
    Filed: May 7, 2015
    Date of Patent: August 6, 2019
    Assignee: cgtx-Peptide Development GmbH
    Inventors: Andreas Klostermann, Jörg Stockhaus
  • Patent number: 10357472
    Abstract: The present application in one aspect provide Fc-containing polypeptide conjugates comprising an Fc-containing polypeptide conjugated to a conjugate moiety, wherein the Fc-containing polypeptide comprises an N-glycosylated Fc region comprising an acceptor glutamine residue flanked by an N-glycosylation site and wherein the conjugate moiety is conjugated to the Fc-containing polypeptide via the acceptor glutamine residue. Also provided are methods of making such Fc-containing polypeptide conjugates by using a wildtype or engineered transglutaminases. Further provided are engineered transglutaminases specifically designed for carrying out such reactions.
    Type: Grant
    Filed: June 11, 2015
    Date of Patent: July 23, 2019
    Assignee: CSPC Dophen Corporation
    Inventors: Sean Hu, Lisha Allen
  • Patent number: 10336766
    Abstract: Enediyne compounds having a structure according to formula (I), where R1, R2, R3, R4, R5, R6, R7 and X are defined herein.
    Type: Grant
    Filed: January 8, 2016
    Date of Patent: July 2, 2019
    Assignee: The Scripps Research Institute
    Inventor: Ben Shen
  • Patent number: 10336812
    Abstract: Fusion proteins containing a half-life extension protein, a linker, and a GDF15 protein are described. Also described are nucleic acids encoding the fusion proteins, recombinant cells thereof, compositions comprising the fusion proteins, and methods of using the fusion proteins for treating or preventing metabolic diseases, disorders or conditions.
    Type: Grant
    Filed: May 4, 2017
    Date of Patent: July 2, 2019
    Assignee: Janssen Biotech, Inc.
    Inventors: Anthony Armstrong, Judith Ann Connor, Jennifer Furman, Chichi Huang, Michael J. Hunter, Xiefan Lin-Schmidt, Serena Nelson, Shamina Rangwala, Shannon Mullican, Jose Antonio Chavez
  • Patent number: 10328148
    Abstract: Compositions and methods that include stabilized protein drugs are described. In addition, protein drug formulations that are more stable under ambient conditions are described. The formulations include one or more poly amino acid ligands of the protein drug.
    Type: Grant
    Filed: March 4, 2016
    Date of Patent: June 25, 2019
    Assignee: Purdue Research Foundation
    Inventors: Elizabeth Murphy Topp, Frederick E. Regnier, Jun Zhang
  • Patent number: 10308703
    Abstract: Death-domain receptor 3 (DR3) variants having increased binding affinity to TL1A, and composition comprising same, are provided. Further, methods of use of said peptides or composition, including, but not limited to treatment of autoimmune and/or inflammatory disease are provided.
    Type: Grant
    Filed: April 27, 2015
    Date of Patent: June 4, 2019
    Assignee: THE NATIONAL INSTITUTE FOR BIOTECHNOLOGY I
    Inventors: Amir Aharoni, Itay Levin
  • Patent number: 10287564
    Abstract: The present disclosure provides protease-activatable procoagulant compounds comprising a procoagulant polypeptide, e.g., a procoagulant peptide and/or clotting factor, and a linker comprising a protease-cleavable substrate (e.g., a synthetic thrombin substrate) and a self-immolative spacer (e.g., p-amino benzyl carbamate). Upon cleavage of the protease-cleavable substrate by a protease (e.g., thrombin), the self-immolative spacer cleaves itself from the procoagulant polypeptide such that the polypeptide is in an underivatized and active form. Also provided are pharmaceutical compositions, methods for treating bleeding disorders using the disclosed compounds, methods of enhancing in vivo efficacy of procoagulant polypeptides, methods of increasing the efficacy of proteolytic cleavage of compounds comprising procoagulant polypeptides, methods of activating procoagulant polypeptides, and methods of releasing a procoagulant polypeptide from a heterologous moiety such as PEG.
    Type: Grant
    Filed: June 7, 2013
    Date of Patent: May 14, 2019
    Assignee: Bioverativ Therapeutics Inc.
    Inventors: Vu Phong Hong, Adam R. Mezo, Joe Salas, Robert T. Peters
  • Patent number: 10287321
    Abstract: The invention provides an agent for preventing or treating a condition characterised by the presence of unwanted cells, the agent comprising: (i) a targeting moiety that is capable of targeting to the unwanted cells; and (ii) a T cell antigen, wherein the T cell antigen can be released from the targeting moiety by selective cleavage of a cleavage site in the agent in the vicinity of the unwanted cells.
    Type: Grant
    Filed: December 16, 2015
    Date of Patent: May 14, 2019
    Assignee: The University of Birmingham
    Inventors: Mark Cobbold, David Millar
  • Patent number: 10280213
    Abstract: Provided herein are HIV-1-specific transforming antibodies (tAbs) and antigens that are recognized by HIV-1-specific tAbs. Also provided herein are methods for screening and/or generating HIV-1-specific tAbs and uses of tAbs for prevention and treatment of HIV-1 infection.
    Type: Grant
    Filed: June 27, 2012
    Date of Patent: May 7, 2019
    Assignee: THE UNIVERSITY OF HONG KONG
    Inventor: Mei-Yun Zhang
  • Patent number: 10274638
    Abstract: The disclosed embodiments include downhole gamma-ray generators and methods to utilize downhole gamma-ray generators in a downhole environment. In one embodiment, a downhole gamma-ray generator includes a target foil formed from a first material. The downhole gamma-ray generator also includes a second layer deposited along a back surface of the target foil. The downhole gamma-ray generator further includes a laser system operable to direct optical pulses onto a front surface of the target foil to ionize atoms of the first material, where electrons produced by ionization of the first material propagate through the target foil and decelerates when the electrons interact with the high density material, and where the deceleration of the electrons produces gamma-rays that are utilized to obtain one or more formation properties of a downhole formation.
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: April 30, 2019
    Assignee: Halliburton Energy Services, Inc.
    Inventors: Juan Navarro Sorroche, Weijun Guo
  • Patent number: 10266631
    Abstract: A peptide-polymer conjugate prepared by a method for preparing a peptide-polymer conjugate according to the present disclosure stably maintains the two-dimensional structure of multiple ?-helix ligands so that its biological interaction is improved while maintaining the specific structure of the peptide ligands.
    Type: Grant
    Filed: January 30, 2017
    Date of Patent: April 23, 2019
    Assignee: INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY
    Inventors: Yong-beom Lim, Young-joo Lee
  • Patent number: 10258684
    Abstract: The present invention relates to novel CD4+ and CD8+ T cell epitopes that are specific for HPV-specific E6 and E7 oncoproteins, to peptides comprising these novel T cell epitopes, and to (vaccine) compositions comprising these peptides for use in methods for the prevention and/or treatment of HPV related diseases. Preferred epitopes are recognized by a T cell that infiltrates a cervical neoplastic lesion or by a T cell from a draining lymph node, and are presented by an HLA-DQ or HLA-DP molecule, or an HLA-B.
    Type: Grant
    Filed: August 16, 2017
    Date of Patent: April 16, 2019
    Assignee: Academisch Ziekenhuis Leiden H.O.D.N. LUMC
    Inventors: Sjoerd Henricus Van Der Burg, Gemma G. Kenter, Cornelis Johannes Maria Melief
  • Patent number: 10251952
    Abstract: Herein is reported a non-covalent complex of a haptenylated antibody that specifically binds to human tau(pS422) and an anti-blood brain barrier receptor/hapten bispecific antibody.
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: April 9, 2019
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Martin Bader, Ulrich Goepfert
  • Patent number: 10253110
    Abstract: The invention provides antibodies against Fibroblast Activation Protein (FAP) and methods of using the same.
    Type: Grant
    Filed: March 18, 2015
    Date of Patent: April 9, 2019
    Assignee: ROCHE GLYCART AG
    Inventors: Marina Bacac, Anne Freimoser-Grundschober, Ralf Hosse, Christian Klein, Ekkehard Moessner, Valeria G. Nicolini, Pablo Umana
  • Patent number: 10232009
    Abstract: Disclosed is a peptide consisting of an amino acid sequence of HisThrSerThrGluAlaLys (SEQ ID NO: 1). This peptide is effective in the enhancement of fibroblast cell migration, which promotes wound healing. Also provided are a pharmaceutical composition for promoting wound healing comprising the peptide, and a method for promoting wound healing using the peptide.
    Type: Grant
    Filed: September 29, 2017
    Date of Patent: March 19, 2019
    Assignee: PRO SUNFUN BIOTECH RESEARCH AND DEVELOPMENT CO., LTD.
    Inventors: Min-Chuan Huang, Syue-Ting Chen, Yu-Chun Liu
  • Patent number: 10233445
    Abstract: The present invention relates to exosomes, loaded with genetic material and methods of producing them and to the use of such exosomes for delivering genetic material in vivo, in particular the use of such exosomes in methods of gene therapy or gene silencing.
    Type: Grant
    Filed: September 8, 2015
    Date of Patent: March 19, 2019
    Assignee: Oxford University Innovation Limited
    Inventors: Yiqi Seow, Lydia Alvarez, Matthew Wood
  • Patent number: 10233229
    Abstract: The present invention relates to monomeric polypeptides comprising an engineered monomeric antibody fragment (e.g., monomeric Fc-containing polypeptides) wherein the monomeric Fc comprises one or more engineered N-linked glycosylation sites in the CH3-CH3 dimerization interface. Methods for producing such engineered monomeric antibody fragments and their use in diagnostics and therapeutics are also provided.
    Type: Grant
    Filed: November 25, 2013
    Date of Patent: March 19, 2019
    Assignee: Pfizer Inc.
    Inventors: Tetsuya Ishino, Weili Duan, Ronald William Kriz
  • Patent number: 10221455
    Abstract: The present disclosure provides methods of administering chimeric and hybrid Factor VIII (FVIII) polypeptides comprising FVIII and Fc to subjects at risk of developing inhibitory FVIII immune responses, including anti-FVIII antibodies and/or cell-mediated immunity. The administration is sufficient to promote coagulation and to induce immune tolerance to FVIII. The chimeric polypeptide can comprise full-length FVIII or a FVIII polypeptide containing a deletion, e.g., a full or partial deletion of the B domain.
    Type: Grant
    Filed: January 12, 2013
    Date of Patent: March 5, 2019
    Assignees: BIOVERATIV THERAPEUTICS INC., PUGET SOUND BLOOD CENTER
    Inventors: Haiyan Jiang, Tongyao Liu, Sriram Krishnamoorthy, Neil Josephson, Glenn Pierce
  • Patent number: 10201572
    Abstract: There is provided herein methods of treating leukemia or lymphoma in a subject in need thereof, with double negative T cells (DNTs) in combination with Interferon-?.
    Type: Grant
    Filed: September 15, 2016
    Date of Patent: February 12, 2019
    Assignee: UNIVERSITY HEALTH NETWORK
    Inventors: Li Zhang, Jong Bok Lee
  • Patent number: 10202595
    Abstract: The invention provides chimeric clotting factors comprising an activatable clotting factor and an enhancer moiety. The activatable clotting factor allows the chimeric clotting factor to be activated at the site of coagulation. The enhancer moiety can additionally improve procoagulation activities of the chimeric clotting factors. The chimeric clotting factors can further be improved by fusion to a half-life extender, which improves a pharmacokinetics property of the chimeric clotting factor. The invention also includes methods of making and methods of using these chimeric clotting factors.
    Type: Grant
    Filed: June 7, 2013
    Date of Patent: February 12, 2019
    Assignee: Bioverativ Therapeutics Inc.
    Inventors: Joe Salas, Elena Kistanova, Vu Phong Hong, Adam R. Meso, Robert T. Peters
  • Patent number: 10195253
    Abstract: Methods and compositions for treating tumors, especially skin tumors, by locally administering single doses of tumor necrosis factor alpha (TNF?) and interleukin-2 (IL2) at the tumor site, where the TNF? and IL2 are delivered as immunoconjugates comprising an antibody targeted to a splice isoform of an extracellular matrix component such as fibronectin.
    Type: Grant
    Filed: June 29, 2012
    Date of Patent: February 5, 2019
    Assignee: PHILOGEN S.P.A.
    Inventor: Kathrin Schwager
  • Patent number: 10197568
    Abstract: This invention provides a base material comprising a plastic-containing support and, on its surface, a hydrophilic layer comprising an ethylene glycol chain (an EG chain) composed of one or more ethylene glycol units, as well as a method for producing such base material. A polysiloxane-containing primer layer is provided on the support comprising a plastic material on its surface, and the EG chain is covalently bound to a polysiloxane side chain of the primer layer. Thus, a hydrophilic layer comprising the EG chain can be provided on the surface of the plastic-containing support.
    Type: Grant
    Filed: April 16, 2012
    Date of Patent: February 5, 2019
    Assignee: Dai Nippon Printing Co., Ltd.
    Inventors: Norihiko Ookouchi, Hirohito Ayame, Yuichi Tanaka, Hiroko Watanabe
  • Patent number: 10188711
    Abstract: The present invention provides compositions comprising peptide-coupled biodegradable poly(lactide-co-glycolide) (PLG) particles In particular, PLG particles are surface-functionalized to allow for coupling of peptide molecules to the surface of the particles (e.g., for use in eliciting induction of immunological tolerance).
    Type: Grant
    Filed: November 2, 2016
    Date of Patent: January 29, 2019
    Assignee: Northwestern University
    Inventors: Lonnie D. Shea, Stephen D. Miller, Jonathan Woon Teck Yap, Daniel R. Getts, Derrick McCarthy
  • Patent number: 10188742
    Abstract: Disclosed herein is a bi-specific antibody that specifically directs a therapeutic agent to a cancer cell by targeting a tumor antigen of the cancer cell, and thereby suppresses the growth of the cancer or blocking the invasion or metastasis of the cancer. The bi-specific antibody of the present disclosure includes a first antigen binding site that binds to polyethylene glycol (PEG); and a second antigen binding site that binds to a target ligand, such as a tumor antigen.
    Type: Grant
    Filed: March 2, 2015
    Date of Patent: January 29, 2019
    Assignee: KAOHSIUNG MEDICAL UNIVERSITY
    Inventors: Steven R Roffler, Tian-Lu Cheng, Chien-Han Kao, Bing-Mae Chen, Yu-Cheng Su, Hsin-Yi Tung, Kuo-Hsiang Chuang
  • Patent number: 10172953
    Abstract: The present invention relates to extended recombinant polypeptide (XTEN) compositions, conjugate compositions comprising XTEN and XTEN linked to cross-linkers useful for conjugation to pharmacologically active payloads, methods of making highly purified XTEN, methods of making XTEN-linker and XTEN-payload conjugates, and methods of using the XTEN-cross-linker and XTEN-payload compositions.
    Type: Grant
    Filed: February 27, 2013
    Date of Patent: January 8, 2019
    Assignee: Amunix Operating Inc.
    Inventors: Volker Schellenberger, Vladimir Podust, Chia-Wei Wang, Bryant McLaughlin, Bee-Cheng Sim, Sheng Ding, Chen Gu